AIRLINK 74.00 Decreased By ▼ -0.25 (-0.34%)
BOP 5.14 Increased By ▲ 0.09 (1.78%)
CNERGY 4.55 Increased By ▲ 0.13 (2.94%)
DFML 37.15 Increased By ▲ 1.31 (3.66%)
DGKC 89.90 Increased By ▲ 1.90 (2.16%)
FCCL 22.40 Increased By ▲ 0.20 (0.9%)
FFBL 33.03 Increased By ▲ 0.31 (0.95%)
FFL 9.75 Decreased By ▼ -0.04 (-0.41%)
GGL 10.75 Decreased By ▼ -0.05 (-0.46%)
HBL 115.50 Decreased By ▼ -0.40 (-0.35%)
HUBC 137.10 Increased By ▲ 1.26 (0.93%)
HUMNL 9.95 Increased By ▲ 0.11 (1.12%)
KEL 4.60 Decreased By ▼ -0.01 (-0.22%)
KOSM 4.83 Increased By ▲ 0.17 (3.65%)
MLCF 39.75 Decreased By ▼ -0.13 (-0.33%)
OGDC 138.20 Increased By ▲ 0.30 (0.22%)
PAEL 27.00 Increased By ▲ 0.57 (2.16%)
PIAA 24.24 Decreased By ▼ -2.04 (-7.76%)
PIBTL 6.74 Decreased By ▼ -0.02 (-0.3%)
PPL 123.62 Increased By ▲ 0.72 (0.59%)
PRL 27.40 Increased By ▲ 0.71 (2.66%)
PTC 13.90 Decreased By ▼ -0.10 (-0.71%)
SEARL 61.75 Increased By ▲ 3.05 (5.2%)
SNGP 70.15 Decreased By ▼ -0.25 (-0.36%)
SSGC 10.52 Increased By ▲ 0.16 (1.54%)
TELE 8.57 Increased By ▲ 0.01 (0.12%)
TPLP 11.10 Decreased By ▼ -0.28 (-2.46%)
TRG 64.02 Decreased By ▼ -0.21 (-0.33%)
UNITY 26.76 Increased By ▲ 0.71 (2.73%)
WTL 1.38 No Change ▼ 0.00 (0%)
BR100 7,874 Increased By 36.2 (0.46%)
BR30 25,596 Increased By 136 (0.53%)
KSE100 75,342 Increased By 411.7 (0.55%)
KSE30 24,214 Increased By 68.6 (0.28%)

Moderna Inc (MRNA.O) on Wednesday reported $6 billion in first-quarter revenue from its COVID-19 vaccine that breezed past estimates, and said it expects vaccine sales to be higher in the second half of the year than in the first.

The company’s shares rose 6.8% to $156.46 before the opening bell. The results eased some worries about vaccine sales this year as an increasing number of people globally receive a complete vaccination course.

Still, future sales remain uncertain as countries relax pandemic curbs, cases fall in some regions and the need for annual booster shots remains unclear.

Moderna, like rival Pfizer (PFE.N), maintained its full-year sales forecast for the vaccine at $21 billion. The bigger drugmaker also stuck to its forecast for its COVID pill, signaling a dearth of new sales contracts for the drug.

Moderna’s vaccine is based on messenger RNA (mRNA), the same technology that is also used by Pfizer, and recently gained authorization for a second booster dose in the United States.

Moderna files for U.S. authorization of COVID shot for kids under 6

U.S. regulators granted authorization for boosters of both vaccines in March for people age 50 and older, citing data showing waning immunity and the risks posed by Omicron variants of the virus.

Moderna Chief Executive Officer Stephane Bancel told CNBC that he hoped people, especially those at high-risk of disease, would get a booster dose in the fall.

Moderna’s COVID shot has propelled it from a developer of experimental vaccine technology with no approved products to a vaccine maker with billions of dollars in sales.

Sales of its vaccine rose to $5.9 billion in the first quarter from $1.7 billion a year ago. Total sales of $6.1 billion beat estimates of $4.62 billion, according to IBES data from Refinitiv.

The company said it expected to test a booster shot to target the Omicron variant, in addition to the original coronavirus, in a late-stage trial in the second quarter.

Comments

Comments are closed.